目的：评价富马酸依美斯汀滴眼液联合氟米龙滴眼液治疗过敏性结膜炎的疗效。

方法：回顾性研究。选取2020-06/2022-08于我院就诊接受治疗的过敏性结膜炎患者115例230眼，在常规使用富马酸依美斯汀滴眼液治疗的同时根据是否联合使用氟米龙滴眼液分为观察组(56例112眼)和对照组(59例118眼)。分别于治疗前、治疗4 wk后评估两组患者的眼部临床症状和体征评分、泪膜破裂时间(BUT)、角膜荧光素染色评分，并记录治疗期间并发症发生情况。

结果：治疗后两组患者眼部症状和体征评分均降低，且观察组低于对照组(P<0.05)； 两组患者BUT均长于治疗前，且观察组长于对照组(P<0.05)； 两组患者角膜荧光素染色评分均降低，且观察组低于对照组(P<0.05)。两组患者治疗期间并发症总发生率(3.6% vs 5.1%)无明显差异(P>0.05)。

结论：富马酸依美斯汀滴眼液联合氟米龙滴眼液治疗过敏性结膜炎可明显减轻患者的眼部症状与体征，延长泪膜破裂时间，降低角膜荧光素染色评分，提高疗效，且不增加并发症发生风险，安全性和有效性较高。

METHODS: Retrospective study. A total of 115 patients(230 eyes)with allergic conjunctivitis who received treatment from June 2020 to August 2022 were selected, and they were divided into the observation group(56 cases, 112 eyes)and the control group(59 cases, 118 eyes)according to whether to use fluorometholone eye drops combined with the conventional use of emedastine difumarate eye drops. The clinical symptoms and signs, tear film break-up time(BUT), corneal fluorescein staining score and complications of the two groups were observed before treatment and at 4 wk after treatment.

RESULTS: After treatment, the scores of eye symptoms and signs in the two groups were decreased, and the observation group was lower than the control group(P<0.05); BUT of the two groups was longer than that before treatment, and the observation group was longer than that of the control group(P<0.05); The corneal fluorescein staining scores of the two groups decreased, and those of the observation group were lower than those of the control group(P<0.05); There was no significant difference in the total incidence of complications between the two groups after treatment(3.6% vs 5.1%; P>0.05).

CONCLUSION: With high therapeutic safety and effectiveness, the combination of emedastine difumarate eye drops and fluorometholone eye drops in the treatment of allergic conjunctivitis can significantly reduce the patient's symptom and sign scores, prolong BUT, promote a decrease in corneal fluorescein staining scores, improve efficacy, and do not increase the risk of complications.